Zosano Pharma Corp Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 16 rows in 2020. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2020-06-03: Reporting owner WALKER JOHN PETER; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2020-06-03: Reporting owner Lo Steven; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2020-06-03: Reporting owner ELMS STEVE; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2020-06-03: Reporting owner Grais Linda S; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2020-06-03 | WALKER JOHN PETER Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,000 15,000 owned after | $1.01 exercise price | 2020-06-05 | |
| 2020-06-03 | Lo Steven Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +292,500 292,500 owned after | $1.01 exercise price | 2020-06-05 | |
| 2020-06-03 | ELMS STEVE Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,000 15,000 owned after | $1.01 exercise price | 2020-06-05 | |
| 2020-06-03 | Grais Linda S Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,000 15,000 owned after | $1.01 exercise price | 2020-06-05 | |
| 2020-06-03 | Grais Linda S Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,000 15,000 owned after | $1.01 exercise price | 2020-06-05 | |
| 2020-06-03 | XANTHOPOULOS KLEANTHIS G Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,000 15,000 owned after | $1.01 exercise price | 2020-06-05 | |
| 2020-06-03 | GREATHOUSE KENNETH Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,000 15,000 owned after | $1.01 exercise price | 2020-06-05 | |
| 2020-06-03 | Hagan Joseph P Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,000 15,000 owned after | $1.01 exercise price | 2020-06-05 | |
| 2020-06-03 | Lewis Hayley Officer (See Remarks) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +37,500 37,500 owned after | $1.01 exercise price | 2020-06-05 | |
| 2020-06-03 | KELLERMAN DONALD J Officer (VP, Clinical Dev & Med Affairs) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +37,500 37,500 owned after | $1.01 exercise price | 2020-06-05 | |
| 2020-06-03 | Matthews Christine Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +37,500 37,500 owned after | $1.01 exercise price | 2020-06-05 | |
| 2020-05-01 | Matthews Christine Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,000 35,000 owned after | $0.70 exercise price | 2020-05-05 | |
| 2020-02-03 holding as of filing | Matthews Christine Officer (See Remarks) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $4.78 exercise price | 2020-02-03 | ||
| 2020-02-03 holding as of filing | Matthews Christine Officer (See Remarks) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $4.78 exercise price | 2020-02-03 | ||
| 2020-02-03 holding as of filing | Matthews Christine Officer (See Remarks) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $2.75 exercise price | 2020-02-03 | ||
| 2020-02-03 holding as of filing | Matthews Christine Officer (See Remarks) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $2.75 exercise price | 2020-02-03 |